Clinical trials: Bioavailability and Pharmacokinetics
Healthy Subjects
Bioavailability and Pharmacokinetic Parameters of Watermelon (Rind, Flesh and Seeds) Polyphenols
The primary objectives of the study are outlined below: 1. To investigate the relative bioavailability and absorption/kinetic profile of polyphenols after consumption of watermelon rind, flesh and seeds, respectively in an acute…
- Trial name
- WM (NCT03365960)
- Testing
- Watermelon Rind, Watermelon Flesh, Watermelon Seeds
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Clinical Nutrition Research Center, Illinois Institute of Technology
Alzheimer Disease
Single Dose Study of ALZ-801 Prototype Tablets
Phase 1, single-center, open-label, non-randomized, sequential single dose 4-period study in 12 healthy subjects to assess the pharmacokinetics of ALZ-801, tramiprosate and the primary metabolite of tramiprosate, NRM5074, from…
- Trial name
- NCT04585347
- Testing
- ALZ-801 170 mg Fasting, ALZ-801 205 mg Fasting, ALZ-801 205 mg After Food
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Alzheon Inc.
Pharmacokinetics
Study of Finerenone to Investigate a Paediatric Formulation in Healthy Male Volunteers
Finerenone is developed for the treatment of diabetic kidney disease (adults) and chronic kidney disease (children). The purpose of the proposed trial is to test the pharmacokinetics of a single oral dose of finerenone (1.25 mg…
- Trial name
- NCT02956109
- Testing
- Finerenone (BAY94-8862): 1 0mg tablet, Finerenone (BAY94-8862): 5 X 0.25 mg oro-dispersible tablets, Finerenone (BAY94-8862): 1.25 mg oro-dispersible tablet
- Where
- Germany
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Bayer
Healthy Volunteers
First in Human Study of ORG-129 in Healthy Volunteers
The current study is performed to characterize the safety, tolerability and pharmacokinetics of ORG-129 after oral intake in healthy male and female volunteers after single ascending and multiple ascending doses.
- Trial name
- NCT04933565
- Testing
- ORG-129
- Where
- Spain
- Volunteers
- 81 people, healthy volunteers welcome
- Sponsor
- Origo Biopharma
Healthy Volunteers
A Study to Assess the Rel Bioavailability, Food Effect and Absolute Bioavailability on the Pharmacokinetics of AZD9833
AstraZeneca AB is developing the test medicine, AZD9833, for the potential treatment of oestrogen receptor (ER) positive breast cancer.
- Trial name
- NCT04546347
- Testing
- [14C]AZD9833 Solution for Infusion, (NMT 22.8 kBq/5mL), AZD9833 film-coated tablet A Dose 1, AZD9833 Oral Solution
- Where
- United Kingdom
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Diabetes Mellitus
A Study to Evaluate the Effect of Food on the Pharmacokinetics of Sotagliflozin and to Explore the Relative Bioavailability in Healthy Subjects
Primary Objective: To evaluate the effect of food on the single-dose pharmacokinetics of sotagliflozin relative to a fasted state in healthy adult male and female subjects.
- Trial name
- NCT03174548
- Testing
- Sotagliflozin (SAR439954)
- Where
- United Kingdom
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Sanofi
Infectious Disease
A Study to Evaluate Effects of Proton-pump Inhibitor on Acalabrutinib Capsule When Administered Orally With COCA-COLA in Healthy Participants
This study is being conducted to support the clinical development of acalabrutinib in participants who need treatment with proton pump inhibitors while taking acalabrutinib.
- Trial name
- NCT04489797
- Testing
- Acalabrutinib, Rabeprazole
- Where
- United States
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Healthy
A Study in Healthy Men to Compare Two Different Oral Formulations of BI 1810631 and to Test How Food or Rabeprazole Influence the Amount of BI 1810631 in the Blood
BI 1810631 trial formulation 1 (TF1) is currently used in clinical trials, but is planned to be replaced by another formulation (principle) in future clinical trials and on the market.
- Trial name
- NCT05380947
- Testing
- BI 1810631 - trial formulation 1 (TF1), BI 1810631 - new formulation (NF), Rabeprazole sodium
- Where
- Germany
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy Volunteers
Bioavailability Study of Naloxone 5 Milligrams (mg) Intramuscular (IM) Autoinjector
To compare the plasma concentration (bioavailability) and safety of a single naloxone 5 mg autoinjector intramuscular (IM) injection to a single 2 mg IM injection (an approved safe dose) and to a single 2 mg bolus intravenous…
- Trial name
- NCT05264493
- Testing
- NaxRedy ™, Naloxone Hydrochloride Injection, USP
- Where
- United States
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- Pfizer
Healthy Volunteers
Study to Evaluatethe Bioavailability and Food Effect Lenalidomide as an Oral Suspension
This study will evaluate the amount of drug that reaches the circulation when a subject takes the test (liquid) formulation compared to the reference (capsule) formulation.
- Trial name
- NCT02521714
- Testing
- Lenalidomide
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Celgene
Healthy Participants
A Study for Multiple Tablet Forms of The Study Medicine (PF-07220060) in Healthy Adults
The purpose of this study is to compare multiple formulations of PF-07220060 in terms of their uptake into the blood stream. The study will assess the effects of food and Rabeprazole on the uptake of PF-07220060.
- Trial name
- NCT05923411
- Testing
- Single dose of PF-07220060 as first Tablet Formulation, Single dose of PF-07220060 as second Tablet Formulation, Single dose of PF-07220060 as a Tablet Formulation
- Where
- United States
- Volunteers
- 113 people, healthy volunteers welcome
- Sponsor
- Pfizer
Healthy
To Assess Safety, Tolerability and Pharmacokinetics of BI 416970 in Healthy Male Volunteers
To investigate the safety and tolerability of BI 416970 and to assess the pharmacokinetics (PK) of single rising doses of BI 416970. A further objective is to assess the influence of CYP2C9 phenotype on the PK of BI 416970.
- Trial name
- NCT02093819
- Testing
- BI 416970
- Where
- Germany
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type 2
A Study Of Three PF-05190457 Formulations In Healthy Volunteers
The purpose of the study is to evaluate the plasma drug concentrations of three formulations of PF-05190457 after administration of single doses to healthy volunteers.
- Trial name
- NCT01522807
- Testing
- PF-05190457
- Where
- Singapore
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Pfizer
Cardiomyopathy
A Phase I Trial on the Relative Bioavailability and Food Effect of HRS-1893 Tablets in Healthy Subjects
This Phase I clinical trial will investigate the relative bioavailability between two formulations of HRS-1893 tablets and the influence of food on the drug's pharmacokinetics in healthy adult participants.
- Trial name
- NCT07272330
- Testing
- HRS-1893 tablet A, HRS-1893 tablet B
- Where
- China
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Shandong Suncadia Medicine Co., Ltd.
Healthy Volunteers
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Bioavailability, and Food-effects of EA1080 in Healthy Caucasian and Japanese Male Participants
The primary purpose of the study is to evaluate the safety and tolerability of EA1080 following single and multiple ascending oral doses in healthy Caucasian and Japanese male participants.
- Trial name
- NCT04223960
- Testing
- EA1080
- Where
- United Kingdom
- Volunteers
- 184 people, healthy volunteers welcome
- Sponsor
- EA Pharma Co., Ltd.
Malaria
Study Assessing Pharmacokinetics and Bioavailability of Three Novel Triazine Compounds
Open-label, randomized, microdose study
- Trial name
- NCT03436160
- Testing
- WR826647, WR909388, WR909390
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- U.S. Army Medical Research and Development Command
Healthy Volunteer Study
Pharmacokinetics of Fixed-Dose Combination Tablet of Bemnifosbuvir and Ruzasvir
This study will assess comparative bioavailability and effect of food on a prototype fixed-dose combination (FDC) of Bemnifosbuvir (BEM) and Ruzasvir (RZR) in healthy subjects
- Trial name
- NCT06204679
- Testing
- Bemnifosbuvir (BEM)/Ruzasvir (RZR) FDC under fasting conditions, Bemnifosbuvir (BEM)/Ruzasvir (RZR) FDC under fed conditions, Bemnifosbuvir (BEM) and Ruzasvir (RZR) as reference formulation under fasting conditions
- Where
- United States
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Atea Pharmaceuticals, Inc.
Parkinson's Disease
Relative Bioavailability Study of HRG2010 in Healthy Subjects
This is a single-center, randomized, open-label, four-period, crossover study. Primary Objective： 1. To evaluate the pharmacokinetic characteristics of healthy subjects after a single oral dose of HRG2010 capsules at dose 1 and…
- Trial name
- NCT06976346
- Testing
- HRG2010 Capsule, Sinemet®, Madopar®
- Where
- China
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Healthy
Pharmacokinetics And Relative Bioavailability Study Of Oxycodone in Healthy Volunteers
To estimate the pharmacokinetics and relative bioavailability of oxycodone after administration of 40 mg doses of PF-00345439 formulations taken whole under fed conditions and after chewing under fasted conditions in healthy…
- Trial name
- NCT01717027
- Testing
- Oxycodone
- Where
- United States
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- Pain Therapeutics
Biological Availability
Drug-drug Interaction (DDI) Study to Assess ODM-201 as a Victim of CYP3A4 Inhibition or Induction
Evaluate the effect of a probe CYP3A4 inhibitor and inducer on the pharmacokinetics of BAY1841788 (ODM-201)
- Trial name
- NCT03048110
- Testing
- BAY1841788 (ODM-201), Itraconazole, Rifampicin
- Where
- Germany
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Bayer